Annual General Meeting of Ypsomed approves all proposals

Press Releases Ypsomed Group

Burgdorf – The Annual General Meeting of Ypsomed Holding AG (SIX: YPSN)  approved all proposals of the Board of Directors on 26 June 2024. Around 500 shareholders attended the event in Burgdorf. They confirmed all members of the Board of Directors in office and re-elected Gilbert Achermann as Chairman of the Board of Directors.

Topics:
Management

Read more...

mylife Loop reaches important milestone toward US approval

Press Releases Ypsomed Group

Burgdorf – The CamAPS FX algorithm has received market authorisation from the United States Food and Drug Administration (FDA). Ypsomed congratulates its partner CamDiab on this achievement and looks forward to further expanding their global partnership. Currently, the mylife YpsoPump is undergoing review by the FDA as an interoperable insulin pump, paving the way for mylife Loop to enter the US market.

Topics:
Access & Expansion

Read more...

medac GmbH chooses Ypsomed autoinjector

Press Releases Ypsomed Group

Burgdorf – medac GmbH has selected an autoinjector from Ypsomed for the relaunch of its methotrexate pen. The YpsoMate 1.0 will gradually replace the current metoject/metex PEN, introducing a model that offers patients enhanced ease of use. The new Ypsomed autoinjector was launched in various countries in the first quarter of 2024.

Topics:
Platforms & Operational Excellence

Read more...

Ypsomed significantly increases its operating profit and plans to have two independent business areas

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 548.5 million in the financial year 2023/24 (previous year: CHF 497.5 million). Adjusted for the sale of the diabetes specialist DiaExpert, this corresponds to growth of 24.5 % or CHF 108.0 million. The operating profit (EBIT) amounted to CHF 86.2 million (previous year: CHF 60.6 million). Adjusted for the previous year's contribution from DiaExpert, this results in EBIT growth of CHF 46.8 million or 119 %. On this basis, Ypsomed was able to more than double its EBIT for the second time in a row. Net profit increased by more than half and now amounts to CHF 78.4 million (previous year: CHF 51.3 million). In future, Ypsomed intends to focus on expanding its leading position in Delivery Systems. To this purpose, it is examining strategic options for the Diabetes Care business area.

Read more...

Ypsomed and ten23 health collaborate for the commercialization of the YpsoDose patch injector

Press Releases Ypsomed Group

Burgdorf – Ypsomed enters a partnership with ten23 health, a global Swiss contract development and manufacturing organization. The aim of this collaboration is to advance the commercialization of the YpsoDose wearable injector for the subcutaneous self-injection of large-volume doses. ten23’s drug development, filling and device assembly expertise will significantly contribute to the product offering.

Topics:
Platforms & Operational Excellence

Read more...